UNSPSC 51291512: Nefazodone

This classification denotes an antidepressant agent with the molecular formula C25H32ClN5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59H4FCV1TF, chemically known as 3h-1,2,4-triazol-3-one, 2,4-dihydro-2-3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-ethyl-4-(2-phenoxyethyl)- but generally known as nefazodone, which bears US NIH Compound Identifier 4449. European Medicines Agency schedules Nefazodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09180MIG.

UNSPSC 51291512 Nefazodone is a Commodity code that in practice captures pharmaceutical procurement across state and local health agencies, though recent opportunities show substantial mismatch between the code's nominal scope and actual solicitation activity. State and local governments are buying naloxone, drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment capabilities under this code. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The code reflects health-focused procurement spanning community health initiatives, pharmacy benefit management, and emergency response supplies rather than the antidepressant medication the code nominally describes.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative reach extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, response due April 3, 2026) to solicit vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers, with awarded vendors effective July 1, 2026. Vendors pursuing this code should expect E-Verify compliance, drug-free workplace certification, professional liability insurance ($2 million floor in MMCAP), compliance with cGMP and DSCSA, and potential FEMA-related federal regulation adherence depending on the issuing body and funding source.